Browse by category

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of ischaemic optic neuropathy (ION) and sudden sight loss of the semaglutide drugs, according to a study by researchers from the University of Ottawa, Ottawa, Ontario, Canada. They found that the risk is almost five times higher with Wegovy than it is with Ozempic, and three times greater in men than it is in women. ION is caused by inadequate/interrupted blood flow to the optic nerve, resulting in sudden vis

Research presented at the 2026 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) has found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be associated with improved short-term postoperative benefits, alongside possible long-term risks of osteoporosis, gout and osteomalacia compared with non-users. “We are just now reaching the precipice where five- and 10-year follow-up data are becoming available for patients taking GLP-1 medications,” sa

The first patient has been dosed in Syntis Bio's the Phase 1/1b SYNTIETY-1 clinical trial of SYNT-101, the company’s lead investigational program for the treatment of obesity. SYNT-101 is designed as a once-daily oral pill that redirects nutrient absorption past the small intestine’s duodenum, mimicking the effects of gastric bypass surgery. SYNT-101 works by transiently blocking nutrient absorption in the duodenum, the upper part of the small intestine, and redirecting nutri

The FDA has approved the premarket approval (PMA) application for the Allurion Gastric Balloon System (AGBS), featuring the Allurion Smart Capsule. The Allurion Program is a weight-loss platform that combines the FDA PMA approved Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, with the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers featuring the Iris AI platform, Allurion Insights for healthcare providers, and the Allurion

A qualitative narrative review by researchers at St George’s University, St George’s, Grenada, has reported that endoscopic sleeve gastroplasty (ESG) represents a safe, minimally invasive and versatile intervention for obesity, occupying a unique position between conservative medical therapy and surgical bariatric procedures. According to the researchers, their review highlights ESG’s ability to produce meaningful weight loss and metabolic improvements while minimising proced

Nonmedical factors drive up to 60 percent of health outcomes, and for people with type 2 diabetes (T2D), social determinants of health factors like poverty, food insecurity, and unstable housing can derail even the best treatment plans. Now, a long-term study led by investigators at Joslin Diabetes Center finds that bariatric metabolic surgery is more effective at glycaemic and weight control than medical and lifestyle interventions for people with T2D, even in the setting of